pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$TGTXTG THERAPEUTICS, INC.

$TGTX62.76-2.71%
New York, NY, USupdated 13h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval10 co-mentions · 5 sources
  • drugBRIUMVI10 co-mentions · 5 sources
  • drugublituximab10 co-mentions · 5 sources
pipeline
3
marketed
1
phase 3
0
catalysts ytd
3
approvals ytd
1
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Marketed: 1Unknown: 2
1Marketed2Unknown
Marketed
ublituximab
Relapsing Multiple Sclerosis (RMS)
drug
BRIUMVI
1 INDICATIONS AND USAGE BRIUMVI is indicated for the trea…
B-lymphocyte antigen CD20
drug
LEROCHOL
1 INDICATIONS AND USAGE LEROCHOL TM is indicated as an ad…

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 2, 2026
earnings
$TGTX62.76-2.71%
15d ago
TG THERAPEUTICS, INC. earnings
TG THERAPEUTICS, INC.
→
view all catalysts →

Active trials

  • phase2Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophreniarecruitingn=60
  • —A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)recruitingn=2,000
  • phase3An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosisactive not recruitingn=1,100
  • —Long-term Follow-up (LTFU) of Participants Who Received Azer-Celrecruitingn=32
  • phase1A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disordersrecruitingn=100
  • phase3A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)active not recruitingn=360
  • phase2A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)recruitingn=350
  • —A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milkrecruitingn=16
🐶 Hiring Signal
No open roles indexed yet — view TG THERAPEUTICS, INC. jobs →

News

  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 7d ago
identifiers
ticker
$TGTX
SEC CIK
0001001316
country
US
source
sec_tickers
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 26m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?